

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

APPLICATION NO.

9516-335-999
(501872-999496)

10/590,575

APPLICANT:

Zeldis

FILING DATE

August 22, 2006

GROUP

1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/S.K./	A01	60/607,408		Muller et al.			9/3/04
/S.K./	A02	60/454,149		Man et al.			3/12/03
/S.K./	A03	60/452,460		Muller et al.			3/5/03
/S.K./	A04	60/452,374		Zeldis et al.			3/6/03
/S.K./	A05	60/438,450		Muller et al.			1/7/03
/S.K./	A06	60/438,448		Muller et al.			1/7/03
/S.K./	A07	10/934,974		Muller et al.			9/3/04
/S.K./	A08	10/900,332		Muller et al.			7/28/04
/S.K./	A09	10/900,270		Muller et al.			7/28/04
/S.K./	A10	10/798,372		Man et al.			3/12/04
/S.K./	A11	10/798,317		Man et al.			3/12/04
/S.K./	A12	10/794,931		Muller et al.			3/5/04
/S.K./	A13	10/748,085		Man et al.			12/29/03
/S.K./	A14	2004/0167199	8/26/04	Muller et al.			
/S.K./	A15	20030187052	10/2/03	Muller et al.			
/S.K./	A16	6,699,899	3/2/04	Man et al.			
/S.K./	A17	6,667,316	12/23/03	Man et al.			
/S.K./	A18	6,518,281	2/11/03	Muller et al.			
/S.K./	A19	6,479,554	11/12/02	Muller et al.			
/S.K./	A20	6,429,221	8/6/02	Muller et al.			
/S.K./	A21	6,326,388	12/4/01	Man et al.			
/S.K./	A22	6,284,780	9/4/01	Muller et al.			
/S.K./	A23	6,262,101	7/17/01	Muller et al.			
/S.K./	A24	6,214,857	4/10/01	Muller et al.			
/S.K./	A25	6,200,987	3/13/01	Muller			
/S.K./	A26	6,180,644	1/30/01	Muller et al.			
/S.K./	A27	6,130,226	10/10/00	Muller et al.			
/S.K./	A28	6,075,041	6/13/00	Muller			
/S.K./	A29	6,046,221	4/4/00	Muller et al.			
/S.K./	A30	6,020,358	2/1/00	Muller et al.			
/S.K./	A31	6,011,050	1/4/00	Muller et al.			
/S.K./	A32	5,968,945	10/19/99	Muller et al.			
/S.K./	A33	5,929,117	7/27/99	Muller et al.			
/S.K./	A34	5,877,200	3/2/99	Muller			
/S.K./	A35	5,801,195	9/1/98	Muller et al.			
/S.K./	A36	5,736,570	4/7/98	Muller et al.			

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

9516-335-999
(501872-999496)

APPLICATION NO.

10/590,575

APPLICANT:

Zeldis

FILING DATE

August 22, 2006

GROUP

1617

/S.K./	A37	5,728,845	3/17/98	Muller et al.			
/S.K./	A38	5,728,844	3/17/98	Muller et al.			
/S.K./	A39	5,703,098	12/30/97	Muller et al.			
/S.K./	A40	5,698,579	12/16/97	Muller			
/S.K./	A41	5,658,940	8/19/97	Muller et al.			
/S.K./	A42	5,605,914	2/25/97	Muller			
/S.K./	A43	5,463,063	10/31/95	Muller			
/S.K./	A44	5,134,127	7/28/92	Stella et al.			
/S.K./	A45	2003/0185826	10/2/03	Tobinick			
/S.K./	A46	2003/0113318	6/19/03	Tobinick			
/S.K./	A47	2003/0049256	3/13/03	Tobinick			
/S.K./	A49	2003/0007972	1/9/03	Tobinick			
/S.K./	A49	2002/0131955	9/19/02	Tobinick			
/S.K./	A56	2002/0131954	9/19/02	Tobinick			
/S.K./	A51	2002/0054899	5/9/02	Zeldis			
/S.K./	A52	2001/0026801	10/4/01	Tobinick			
/S.K./	A51	2001/0016195	8/23/01	Tobinick			
/S.K./	A59	2001/0004456	6/21/01	Tobinick			
/S.K./	A59	6,623,736	9/23/03	Tobinick			
/S.K./	A56	6,537,549	3/25/03	Tobinick			
/S.K./	A57	6,471,961	10/29/02	Tobinick			
/S.K./	A59	6,428,787	8/6/02	Tobinick			
/S.K./	A59	6,423,321	7/23/02	Tobinick			
/S.K./	A60	6,419,934	7/16/02	Tobinick			
/S.K./	A61	6,419,934	7/16/02	Tobinick			
/S.K./	A62	6,379,666	4/30/02	Tobinick			
/S.K./	A63	6,297,286	10/2/01	Huckle			
/S.K./	A63	6,177,077	1/23/01	Tobinick			
/S.K./	A65	6,015,557	1/18/00	Tobinick et al.			
/S.K./	A66	5,929,117	7/27/99	Muller et al.			
/S.K./	A67	5,877,200	3/2/99	Muller			
/S.K./	A68	5,739,119	4/14/98	Galli et al.			
/S.K./	A69	5,698,579	12/16/97	Muller			
/S.K./	A70	5,434,170	7/18/95	Andrulis			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/S.K./	B01	WO 03/080048	10/2/03	PCT				
/S.K./	B02	WO 03/080049	10/2/03	PCT				

/S.K./	B03	WO 01/45702	6/28/01	PCT				
/S.K./	B04	WO 01/34606	5/17/01	PCT				
/S.K./	B05	WO 99/06041	2/11/99	PCT				
/S.K./	B06	WO 97/23457	7/3/97	PCT				
/S.K./	B07	WO 97/08143	3/6/97	PCT				
/S.K./	B08	WO 95/01348	1/12/95	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/S.K./	C01	Akaike et al., 1993, "Rolipram enhances the development of voltage-dependent Ca ²⁺ current and serotonin-induced current in rat pheochromocytoma cells," <i>Brain Res.</i> 620(1):58-63
/S.K./	C02	Auluck et al., 2002, "Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease," <i>Science</i> 295(5566):865-868
/S.K./	C03	Bancher et al., 1989, "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease," <i>Brain Res.</i> 477(1-2):90-99
/S.K./	C04	Banta et al., 1977, "Elevated manganese levels associated with dementia and extrapyramidal signs," <i>Neurology</i> 27(3):213-216
/S.K./	C05	Baraitser, 1990, <i>The Genetics of Neurological Disorders</i> , 2 nd ed., pp. 85-88
/S.K./	C06	Bourchouladze et al., 2003, "A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4," <i>Proc. Natl. Acad. Sci. USA</i> 100(18):10518-10522
/S.K./	C07	Calne et al., 1987, "Familial Parkinson's disease: possible role of environmental factors," <i>Can. J. Neurol. Sci.</i> 14(3):303-305
/S.K./	C08	Caraceni et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression," <i>Neurology</i> 41(3):380-384
/S.K./	C09	Casacchia et al., 1983, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," <i>Pharmacol. Res. Commun.</i> 15(3):329-334
/S.K./	C10	Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," <i>J. Comp. Neurol.</i> 407(2):287-301
/S.K./	C11	Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," <i>Ann. Rheum. Dis.</i> 58(Suppl. 1):1107-1113
/S.K./	C12	Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," <i>Brain</i> 99(1):67-80
/S.K./	C13	Crook et al., 1986, <i>Dev. Neuropsychol.</i> 2:261-276
/S.K./	C14	Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," <i>J. Neurol. Neurosurg. Psychiatry</i> 66(2):137-147
/S.K./	C15	Freo et al., 2001, "Effects of Acetylcholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasiltmine," <i>Soc. Neurosci. Abstr.</i> 677.5
/S.K./	C16	Gilroy et al., 1979, <i>Medical Neurology</i> , MacMillan Publishing Co., pp. 175-179
/S.K./	C17	Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," <i>Proc. Natl. Acad. Sci. USA</i> 83(13):4913-4917
/S.K./	C18	Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," <i>Anal. Chem.</i> 44(2):416-417
/S.K./	C19	Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," <i>Eur. J. Neurosci.</i> 7(12):2431-2440
/S.K./	C20	Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," <i>J. Neural. Transm. Suppl.</i> 46:217-228
/S.K./	C21	Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," <i>Ann. Neurol.</i> 23(4):371-379
/S.K./	C22	Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinoma stem cell line," <i>Brain Res.</i> 912(1):99-104
/S.K./	C23	Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," <i>Science</i> 290(5492):767-773
/S.K./	C24	Kosik, 1990, "Tau protein and Alzheimer's disease," <i>Curr. Opin. Cell. Biol.</i> 2(1):101-104
/S.K./	C25	Kral, 1962, "Senescent forgetfulness: benign and malignant," <i>Can. Med. Assoc. J.</i> 86:257-260
/S.K./	C26	Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," <i>Int. Psychogeriatr.</i> 6(1):63-68
/S.K./	C27	Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," <i>Science</i> 298(5592):425-429
/S.K./	C28	Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," <i>Am. J. Med. Genet.</i> 109(3):191-197
/S.K./	C29	McGeer et al., 2001, <i>B.C. Med. J.</i> 43:138-141
/S.K./	C30	Merritt, 1979, <i>A Textbook of Neurol.</i> , 6 th ed., Lea & Febiger, Philadelphia, pp. 484-489
/S.K./	C31	Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," <i>Exp. Neurol.</i> 158(2):469-490
/S.K./	C32	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," <i>Bioorg. Med. Chem. Lett.</i> 9(11):1625-1630

/S.K./	C33	Nussbaum et al., 1997, "Genetics of Parkinson's disease," <i>Hum. Mol. Genet.</i> 6(10):1687-1691
/S.K./	C34	Olson, 2000, "Biomedicine. Combating Parkinson's disease—step three," <i>Science</i> 290(5492):721-724
/S.K./	C35	Parkes et al., 1984, "Risperidone in Parkinson's disease," <i>Adv. Neurol.</i> 40:563-565
/S.K./	C36	Petersen et al., 2001, "Current concepts in mild cognitive impairment," <i>Arch. Neurol.</i> 58(12):1985-1992
/S.K./	C37	Petersen et al., 1999, "Mild cognitive impairment: clinical characterization and outcome," <i>Arch. Neurol.</i> 56(3):303-308
/S.K./	C38	Petersen et al., 1995, "Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals," <i>JAMA</i> 273(16):1274-1278
/S.K./	C39	Polymeropoulos et al., 1995, "Mapping of a gene for Parkinson's disease to chromosome 4q21-q23," <i>Science</i> 274(5290):1197-1199
/S.K./	C40	Price et al., 1999, "Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease," <i>Ann. Neurol.</i> 45(3):358-368
/S.K./	C41	Rabe et al., 1982, "Enhancement of depolarization-dependent neurosecretion from PC12 cells by forskolin-induced elevation of cyclic AMP," <i>J. Cyclic. Nucleotide Res.</i> 8(6):371-384
/S.K./	C41	Rousselet et al., 2002, "Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP," <i>Exp. Neurol.</i> 177(1):183-192
/S.K./	C63	Sriram et al., 2002, "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease," <i>FASEB J.</i> 16(11):1474-1476
/S.K./	C63	Takahashi et al., 1999, "Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms," <i>J. Neurosci.</i> 19(2):610-618
/S.K./	C45	Traynor et al., 1984, "Phospholipases elevate cyclic AMP levels and promote neurite extension in a clonal nerve cell line," <i>Dev. Brain Res.</i> 316(2):197-204
/S.K./	C66	Troncoso et al., 1996, "Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging," <i>Neurobiol. Aging</i> 17(3):365-371
/S.K./	C47	Westlund et al., 1992, "Effects of nerve growth factor and acetyl-L-carnitine arginyl amide on the human neuronal line HCN-1A," <i>Int. J. Dev. Neurosci.</i> 10(5):361-373
/S.K./	C48	Wolff, ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 th ed., pp. 172-178 and 949-982
/S.K./	C43	Wolozin et al., 1987, "Alzheimer-related neuronal protein A68: specificity and distribution," <i>Ann. Neurol.</i> 22(4):521-526
/S.K./	C50	Zhu et al., 2001, "The antidepressant and antiinflammatory effects of risperidone in the central nervous system," <i>CNS Drug Rev.</i> 7(4):387-398
/S.K./	C59	Engelhart et al., 2002, "Dietary intake of antioxidants and risk of Alzheimer Disease," <i>J. Am. Med. Assoc.</i> 287(24):3223-3229
/S.K./	C57	Foley et al., 2002, "Dietary intake of antioxidants and risk of Alzheimer Disease," <i>J. Am. Med. Assoc.</i> 287(24):3261-3263
/S.K./	C53	Morris et al., 2002, "Dietary intake of antioxidant nutrients and the risk of incident Alzheimer Disease in a biracial community study," <i>J. Am. Med. Assoc.</i> 287(24):3230-3237
/S.K./	C56	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," <i>Bioorg. Med. Chem. Lett.</i> 8(19):2669-2674
/S.K./	C59	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," <i>J. Med. Chem.</i> 39(17):3238-3240
/S.K./	C56	Physician's Desk Reference, 2002, 56 th ed., pp. 1755-1760
/S.K./	C57	Saha et al., 2003, "Tumor necrosis factor- α at the crossroads of neuronal life and death during HIV-associated dementia," <i>J. Neurochem.</i> 86:1057-1071
/S.K./	C56	Wolff, ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 th ed. 172-178, 949-982
/S.K./	C56	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," <i>Curr. Opin. Investig. Drugs</i> 4(6):667-673
/S.K./	C60	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," <i>Crit. Rev. Immunol.</i> 22(5-6):425-437
/S.K./	C63	DREDGE et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," <i>Br. J. Cancer</i> 87(10):1166-1172
/S.K./	C62	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," <i>Expert Opin. Biol. Ther.</i> 2(8):953-966
/S.K./	C63	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," <i>Cancer Res.</i> 63(23):8073-8078
/S.K./	C63	MARRIOTT et al., 2001, "Immunotherapeutic and antitumor potential of thalidomide analogues," <i>Expert Opin. Biol. Ther.</i> 1(4):1-8
/S.K./	C66	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," <i>Clin. Exp. Immunol.</i> 130(1):75-84
/S.K./	C66	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," <i>Br. J. Haematol.</i> 124(3):366-375
/S.K./	C67	ZELDIS et al., 2003, "Potential new therapeutics for Waldenstrom's macroglobulinemia," <i>Semin. Oncol.</i> 30(2):275-281

EXAMINER /Shobha Kantamneni/

DATE CONSIDERED 03/03/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.